XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) has expanded its exclusive development agreement with Prof. Dr. Raimar Löbenberg to include psychedelic compounds such as psilocybin, mescaline, LSD, MDMA, and DMT. This addition is aimed at leveraging the therapeutic potential of these compounds for treating mental health issues. The agreement enhances XPhyto's capabilities in developing standardized drug formulations for clinical use. Dr. Löbenberg, an expert in biopharmaceutics, emphasizes the goal of creating precise drug delivery systems. The psychedelic drugs are gaining recognition for their potential benefits in mental health treatments.
XPhyto Therapeutics Corp (CSE:XPHY, OTCQB:XPHYF) has appointed Per S. Thoresen to its board of directors, effective immediately. Thoresen brings 25 years of pharmaceutical experience, including executive roles at major firms and a successful tenure as managing director at Nycomed Pharma. The company also announced a strategic partnership with CorpCann AS, enhancing its Europe-focused strategy. Thoresen will receive 250,000 stock options as part of his role. This leadership change aims to bolster XPhyto’s advancement in drug delivery and diagnostics, with products nearing commercialization.
XPhyto Therapeutics Corp has appointed Per S. Thoresen, an experienced pharma executive, to its board, effective immediately. Thoresen brings 25 years of experience, including a role as managing director at Nycomed Pharma, acquired by Takeda for approximately USD $14B. His expertise is expected to enhance XPhyto's strategy as several products near commercialization. Additionally, XPhyto has engaged with CorpCann AS, which will support its European-focused growth strategy. As part of the appointment, Thoresen received 250,000 stock options exercisable at $1.80 over five years.
XPhyto Therapeutics Corp. (CSE:XPHY, OTC:XPHYF) has announced a rapid 25-minute RT-PCR test for COVID-19, developed by its partner 3a-Diagnostics. This test, alongside a 15-minute rapid test, is set for commercial launch in Europe in Q1 2021. The RT-PCR system, designed for laboratory use, promises results in under 25 minutes with minimal equipment. Validation studies are planned in Germany for Q4 2020. The partnership includes exclusive commercialization rights for both testing systems, advancing XPhyto's position in the diagnostics market.
XPhyto Therapeutics Corp (CSE:XPHY / OTCQB:XPHYF) announced developments from its German subsidiary, Vektor Pharma TF GmbH, regarding a new oral disintegrating film (ODF) dosage formulation for a major generic drug company.
Vektor recently completed manufacturing clinical trial materials for evaluation. The ODF technology supports quick adjustments to formulation based on various active pharmaceutical ingredients (APIs).
As the global thin film drug market is projected to reach USD $29.2 billion by 2024, XPhyto is working on enhancing drug delivery systems and plans to update on its COVID-19 screening test development soon.
XPhyto Therapeutics Corp (CSE:XPHY, OTC:XPHYF) announced advancements in its oral disintegrating film (ODF) drug delivery programs, focusing on cannabidiol (CBD) and tetrahydrocannabinol (THC). The company’s subsidiary, Vektor Pharma, is developing ODFs designed to enhance bioavailability and provide faster drug action. Initial data shows a 5-fold increase in CBD bioavailability compared to oil-based methods. The global thin film drug market is projected to reach USD $29.2 billion by 2024. XPhyto is exploring additional ODF opportunities, including a 1:1 CBD/THC formula for MS-induced spasticity.
XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) will present at the Virtual Life Sciences Forum on September 17, 2020, at 1:00 PM Eastern Time. CEO Hugh Rogers will discuss developments in Germany regarding a rapid COVID-19 screening test and innovative drug delivery methods. The company collaborates with 3a-Diagnostics GmbH on a point-of-care test for COVID-19 viral RNA detection. Additionally, XPhyto is advancing dosage forms for conventional and cannabis-based narcotics. The event is open to investors, with registration available online.
XPhyto Therapeutics Corp (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) has provided an update on its rapid COVID-19 screening test development in partnership with 3a-Diagnostics GmbH.
The test aims to detect COVID-19 viral RNA from saliva and swab samples. Following successful validation of a prototype, the company anticipates advanced prototype production and usability testing in Q4 2020. XPhyto is also developing tests for other viruses, with funding from the German Federal Ministry of Education and Research. While the scientific landscape surrounding COVID-19 continues to evolve, XPhyto is focusing on low-cost, decentralized screening solutions.
XPhyto Therapeutics Corp (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) has announced that its common shares are now trading on the OTCQB Venture Market. This platform is known for early-stage companies and requires compliance with reporting and verification standards. Additionally, XPhyto's shares are eligible for electronic settlement by The Depository Trust Company, enhancing their trading capabilities in the U.S. The company continues to trade on the Canadian Securities Exchange and Frankfurt Stock Exchange, focusing on innovative drug delivery and pathogen screening technologies.